{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:07Z","timestamp":1793781847435,"version":"4.6.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002875","name":"Chunghwa Telecom Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019254","name":"ReShape Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103647","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:51:42Z","timestamp":1722973902000},"page":"103647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7167","authenticated-orcid":false,"given":"L.-T.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Pangarsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.O.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Regala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tanasanvimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Charoentum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Jeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-Y.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.-J.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103647_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/CMAR.S157156","article-title":"Biliary tract cancer: current challenges and future prospects","volume":"11","author":"Ghidini","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","article-title":"Worldwide incidence and mortality of biliary tract cancer","volume":"1","author":"Baria","year":"2022","journal-title":"Gastro Hep Advances"},{"key":"10.1016\/j.esmoop.2024.103647_bib3","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/CMAR.S157092","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges","volume":"11","author":"Tariq","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ijc.33210","article-title":"Diagnosis of digestive system tumours","volume":"148","author":"Washington","year":"2021","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visc Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.5009\/gnl.2013.7.6.719","article-title":"Changes in demographic features of gallstone disease: 30 years of surgically treated patients","volume":"7","author":"Chang","year":"2013","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0039-6060(96)80071-7","article-title":"Surgical treatment of hepatolithiasis: long-term results","volume":"120","author":"Jan","year":"1996","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103647_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1440-1746.1991.tb01457.x","article-title":"Hepatolithiasis in East Asia: comparison between Japan and China","volume":"6","author":"Nakayama","year":"1991","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2024.103647_bib11","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.2741\/1091","article-title":"Hepatolithiasis--epidemiology and pathogenesis update","volume":"8","author":"Shoda","year":"2003","journal-title":"Front Biosci"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jiab401","article-title":"Universal infant hepatitis B virus (HBV) vaccination for 35 Years: moving toward the eradication of HBV","volume":"225","author":"Chang","year":"2022","journal-title":"J\u00a0Infect Dis"},{"issue":"30","key":"10.1016\/j.esmoop.2024.103647_bib13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.15585\/mmwr.mm6930a2","article-title":"Progress toward hepatitis B control - South-East Asia region, 2016-2019","volume":"69","author":"Sandhu","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3904\/kjim.2019.007","article-title":"The epidemiology of hepatitis B virus infection in Korea","volume":"34","author":"Yim","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103647_bib15","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/hbsn-21-75","article-title":"Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries","volume":"12","author":"An","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103647_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/jhbp.116","article-title":"Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years","volume":"21","author":"Suzuki","year":"2014","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib18","first-page":"605","article-title":"Risk factors for cholangiocarcinoma in Thailand: a systematic review and meta-analysis","volume":"19","author":"Kamsa-ard","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.14701\/ahbps.22-041","article-title":"Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019","volume":"26","author":"Kang","year":"2022","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.esmoop.2024.103647_bib20","year":"2023","journal-title":"Cancer statistics in Japan"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/s12889-019-7160-z","article-title":"Favorable gallbladder cancer mortality-to-incidence ratios of countries with good ranking of world's health system and high expenditures on health","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103647_bib24","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/cam4.915","article-title":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","volume":"5","author":"Koshiol","year":"2016","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103647_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/apt.12655","article-title":"Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer","volume":"39","author":"Nagaraja","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2024.103647_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8886085","article-title":"The relationship between Helicobacter pylori infection of the gallbladder and chronic cholecystitis and cholelithiasis: a systematic review and meta-analysis","volume":"2021","author":"Wang","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.22756","article-title":"Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China","volume":"121","author":"Hsing","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12885-020-07139-y","article-title":"Effect of diabetes mellitus on survival in patients with gallbladder cancer: a systematic review and meta-analysis","volume":"20","author":"Jing","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103647_bib29","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.3390\/nu7105387","article-title":"Body mass index and risk of gallbladder cancer: systematic review and meta-analysis of observational studies","volume":"7","author":"Tan","year":"2015","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1158\/1055-9965.EPI-16-0796","article-title":"Body size indicators and risk of gallbladder cancer: pooled analysis of individual-level data from 19 prospective cohort studies","volume":"26","author":"Campbell","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.esmoop.2024.103647_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.12659\/MSMBR.901651","article-title":"Body mass index can increase the risk of gallbladder cancer: a meta-analysis of 14 cohort studies","volume":"22","author":"Liu","year":"2016","journal-title":"Med Sci Monit Basic Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.31835","article-title":"Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults","volume":"144","author":"McGee","year":"2019","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103647_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103647_bib36","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103647_bib37","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3348\/kjr.2019.0803","article-title":"Radiologic evaluation and structured reporting form for extrahepatic bile duct cancer: 2019 consensus recommendations from the Korean Society of Abdominal Radiology","volume":"22","author":"Lee","year":"2021","journal-title":"Korean J Radiol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1148\/radiol.212132","article-title":"Multidetector CT of extrahepatic bile duct cancer: diagnostic performance of tumor resectability and interreader agreement","volume":"304","author":"Lee","year":"2022","journal-title":"Radiology"},{"issue":"40","key":"10.1016\/j.esmoop.2024.103647_bib42","doi-asserted-by":"crossref","first-page":"11481","DOI":"10.3748\/wjg.v21.i40.11481","article-title":"Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: a meta-analysis","volume":"21","author":"Annunziata","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103647_bib43","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3348\/kjr.2019.0891","article-title":"Diagnostic performance and prognostic relevance of FDG positron emission tomography\/computed tomography for patients with extrahepatic cholangiocarcinoma","volume":"21","author":"Kim","year":"2020","journal-title":"Korean J Radiol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3348\/kjr.2020.0689","article-title":"Additional value of integrated (18)F-FDG PET\/MRI for evaluating biliary tract cancer: comparison with contrast-enhanced CT","volume":"22","author":"Yoo","year":"2021","journal-title":"Korean J Radiol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.103647_bib45","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.3748\/wjg.v26.i25.3542","article-title":"Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma","volume":"26","author":"Dondossola","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejso.2016.05.026","article-title":"The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review","volume":"43","author":"Glantzounis","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib47","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/bjs5.50273","article-title":"Effect of structured use of preoperative portal vein embolization on outcomes after liver resection of perihilar cholangiocarcinoma","volume":"4","author":"Franken","year":"2020","journal-title":"BJS Open"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.sla.0000201482.11876.14","article-title":"Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up","volume":"243","author":"Nagino","year":"2006","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jso.21141","article-title":"Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)","volume":"98","author":"Duffy","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib50","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/SLA.0b013e31806beec2","article-title":"Gallbladder cancer: the role of laparoscopy and radical resection","volume":"245","author":"Shih","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103647_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1245\/s10434-011-1850-9","article-title":"Is port site resection necessary in the surgical management of gallbladder cancer?","volume":"19","author":"Maker","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2024.103647_bib52","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3748\/wjg.v18.i30.4019","article-title":"Incidental gallbladder cancer during laparoscopic cholecystectomy: managing an unexpected finding","volume":"18","author":"Cavallaro","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib53","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/jso.24591","article-title":"Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium","volume":"115","author":"Ethun","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib54","first-page":"277","article-title":"Is port-site resection necessary in the surgical management of gallbladder cancer?","volume":"150","author":"Fuks","year":"2013","journal-title":"J\u00a0Visc Surg"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103647_bib56","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"10372","key":"10.1016\/j.esmoop.2024.103647_bib57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103647_bib58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.2022.40.4_suppl.382","article-title":"Adjuvant S-1 versus observation in curatively resected biliary tract cancer: a phase III trial (JCOG1202: ASCOT)","volume":"40","author":"Ikeda","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103647_bib59","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib60","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1245\/s10434-022-12863-9","article-title":"Adjuvant chemoradiation in patients with lymph node-positive biliary tract cancers: secondary analysis of a single-arm clinical trial (SWOG 0809)","volume":"30","author":"Gholami","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib61","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","article-title":"Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection","volume":"221","author":"Groot","year":"2015","journal-title":"J\u00a0Am Coll Surg"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103647_bib62","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12094-017-1815-y","article-title":"Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma","volume":"20","author":"Lee","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib63","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1016\/j.ijrobp.2010.12.019","article-title":"Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103647_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4143\/crt.2015.091","article-title":"Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected extrahepatic bile duct cancer: treatment outcome analysis of 336 patients","volume":"48","author":"Im","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000518298","article-title":"Adjuvant radiotherapy for extrahepatic cholangiocarcinoma: a quality assessment-based meta-analysis","volume":"10","author":"Choi","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.esmoop.2024.103647_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103647_bib67","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jso.27435","article-title":"Tumor size and survival in intrahepatic cholangiocarcinoma treated with surgical resection or ablation","volume":"128","author":"Kanu","year":"2023","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103647_bib68","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000522403","article-title":"Liver Cancer Study Group of Japan Clinical Practice Guidelines for intrahepatic cholangiocarcinoma","volume":"11","author":"Kubo","year":"2022","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/hbsn.2016.09.07","article-title":"Ablative therapies for intrahepatic cholangiocarcinoma","volume":"6","author":"Shindoh","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103647_bib70","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/cancers15082384","article-title":"Locoregional therapy for intrahepatic cholangiocarcinoma","volume":"15","author":"Owen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib72","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamasurg.2022.1298","article-title":"Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma","volume":"157","author":"Franssen","year":"2022","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103647_bib73","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","article-title":"Drug-Eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib74","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"10.1016\/j.esmoop.2024.103647_bib75","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103647_bib77","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"issue":"16-18","key":"10.1016\/j.esmoop.2024.103647_bib78","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/ars.2021.0183","article-title":"Cisplatin chemotherapy and cochlear damage: otoprotective and chemosensitization properties of polyphenols","volume":"36","author":"Fetoni","year":"2022","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","article-title":"An integrated view of cisplatin-induced nephrotoxicity and ototoxicity","volume":"237","author":"Karasawa","year":"2015","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.esmoop.2024.103647_bib80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine\u00a0+ cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib81","first-page":"110","article-title":"A\u00a0phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma","volume":"5","author":"Julka","year":"2006","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103647_bib82","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1477-2574.2010.00197.x","article-title":"Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study","volume":"12","author":"Williams","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib83","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103647_bib84","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A\u00a0randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103647_bib85","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103647_bib86","first-page":"S563","article-title":"53MO Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103647_bib87","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaoncol.2020.6166","article-title":"Efficacy of capecitabine plus irinotecan vs irinotecan monotherapy as second-line treatment in patients with advanced gallbladder cancer: a multicenter phase 2 randomized clinical trial (GB-SELECT)","volume":"7","author":"Ramaswamy","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib88","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103647_bib89","first-page":"54","article-title":"PARP inhibitors in biliary tract cancer: a new kid on the block?","volume":"7","author":"Ricci","year":"2020","journal-title":"Medicines (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib90","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","article-title":"Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA cariants: findings from 2 phase 2 nonrandomized clinical trials","volume":"7","author":"Javle","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103647_bib91","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103647_bib92","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103647_bib93","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103647_bib95","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib96","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2024.103647_bib97","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract vancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103647_bib98","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-naive human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103647_bib99","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET abberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103647_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103647_bib101","unstructured":"US Food and Drug Administration. FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. 2022. Available at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors. Accessed 13 February 2024."},{"issue":"10","key":"10.1016\/j.esmoop.2024.103647_bib102","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103647_bib103","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.esmoop.2024.103647_bib104","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211062324","article-title":"Tumor mutational burden as a biomarker for advanced biliary tract cancer","volume":"20","author":"Kim","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2024.103647_bib105","article-title":"Tumor mutational burden is a potential predictive biomarker for response to immune checkpoint inhibitors in patients with advanced biliary tract cancer","volume":"6","author":"Liddell","year":"2022","journal-title":"JCO Precis Oncol"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2024.104074","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:07:02Z","timestamp":1737331622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924014169"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103647","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.esmoop.2024.104074","asserted-by":"object"}]},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103647"}}